Labiotech.eu

News and Trends 13 Jan 2017

UPDATE: J&J and Actelion settle on a price, R&D assets will be spun out

UPDATE (12/01/2017): J&J and Actelion have reportedly settled on a price: $260 (€245) per share, totaling more than $28 (€26) billion. The Swiss biotech’s R&D assets will be spun out into a new company that will remain independent. UPDATE (03/01/2017): The deal has veered towards splitting Actelion into two companies, one for its commercialized portfolio […]

January 13, 2017 - 4 minutesmins - By Clara Rodríguez Fernández

News and Trends 12 Jan 2017

An Antibody to reduce Hospitalizations of Children starts Phase IIb trials

Ablynx has treated its first patient in a new trial targeting RSV infections, the main cause of children hospitalizations. Ablynx, one of the few European biotechs that made it into JP Morgan this year, develops nanobodies derived from llamas. The Belgian company announced yesterday that its candidate ALX-0171 has entered testing in Phase IIb as a treatment […]

January 12, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Screenshot 2017 01 12 at 11.39.33 AM e1484217679930

More News! 12 Jan 2017

German Microscopy Tech raises funds to take over Imaging in Biology

Luxendo has raised €8M to start international sales of its unique microscopy technology aiming to take over confocal microscopes in biology research. Luxendo, a spin-out from the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany, has closed its Series A fundraising round led by Life Science Partners (LSP), one of the best European biotech VCs. The total €8M raised will be […]

January 12, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 12 Jan 2017

Antibody Treatment for Obesity and Type 2 Diabetes enters Phase II

Novartis is initiating Phase II trials with an antibody licensed from German biotech MorphoSys that tackles the obesity and diabetes epidemic. MorphoSys is a billion euro biotech that develops therapeutic antibodies for big names like Bayer, Pfizer, GSK, Boehringer Ingelheim, Roche and Janssen. The company is now adding type 2 diabetes to its long list of indications; bimagrumab will start Phase […]

January 12, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 11 Jan 2017

Phase II Failure: CureVac’s CEO explains Missed Efficacy Endpoint

Money doesn’t guarantee success, even if it’s heavy investment from the likes of the Bill & Melinda Gates Foundation. Ingmar Hoerr explains what it means for mRNA therapeutics. In a blow to the field of mRNA, the German billion-euro biotech CureVac has reported the Phase II failure of its lead candidate at JP Morgan. Aimed at prostate cancer, CV9104 did not […]

January 11, 2017 - 4 minutesmins - By Evelyn Warner

News and Trends 11 Jan 2017

Merck expands its Oncology Pipeline beyond Checkpoint Inhibitors

Merck is diversifying its oncology portfolio with four new programs licensed from Vertex Pharmaceuticals, including multiple DNA damage and repair drugs. Merck has entered a licensing agreement with Boston-based Vertex Pharmaceuticals for the worldwide rights to four oncology programs. Merck has paid €220M ($230M) upfront for two clinical-stage DNA damage and repair candidates and two additional […]

January 11, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Best in Biotech 11 Jan 2017

UPDATE: The 5 Hottest European Biotechs in 2017 according to JP Morgan

The world’s biggest biotech investor conference, hosted by JP Morgan, is now underway in San Francisco, and European companies are putting up a strong showing. Here are those (in chronological order) who made the cut to present at this invite-only event. We’ll update the post as companies present! While uniQure has hit a number of rough […]

January 11, 2017 - 3 minutesmins - By Evelyn Warner

News and Trends 11 Jan 2017

Dutch Biotech Takes over Sustainable Coca Cola Bottles Project

Avantium has acquired Liquid Light, getting hold of the last piece of technology it requires to create the next generation of sustainable Coca Cola bottles. Avantium, a spin-off from Shell located in Amsterdam, is one of Coca Cola’s choices to develop its next-generation plastic bottles made 100% from plant-based materials. The biotech is now stepping up […]

January 11, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 10 Jan 2017

Stem Cells in your Teeth can be Stimulated to Naturally Repair Cavities

Researchers from the UK have described a new treatment for cavities that could get rid of fillings and cements by employing an Alzheimer’s drug. Most of us have visited the dentist to fill a cavity. The usual procedure involves removing the damaged area and replacing it with mineral materials. But what if you could let […]

January 10, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 10 Jan 2017

Qiagen acquires Multi Omics Company to boost its Bioinformatics services

Qiagen is entering the promising field of multi-omics data analysis with the acquisition of a bioinformatics company from the US. Qiagen, an upstart looking to break into the field of next-generation sequencing (NGS), has just announced the acquisition of US-based OmicSoft for an undisclosed amount. This transaction will upgrade Qiagen’s bioinformatics services, which will now include multi-omics data analysis and software […]

January 10, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 9 Jan 2017

Top European VC and CRO fund Young Metabolic Disease Biotech

Eternygen has received €8M in a Series A round led by Epidarex Capital that will be used to advance its pipeline in collaboration with Evotec. Eternygen is a young biotech in Berlin focusing on the treatment of metabolic diseases. The company has now raised €8M in Series A, led by Scottish biotech VC Epidarex Capital. Among the […]

January 9, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Screenshot 2017 01 09 at 12.40.51 PM e1483962109441

News and Trends 9 Jan 2017

German Immuno-Oncology Biotech partners up with Biotech Giant Amgen

Immatics and Amgen have inked a deal to develop bispecific drug candidates for cancer that could reach over €1B in milestones. Immatics, an immuno-oncology biotech in Tübingen, Germany, has signed an agreement with biotech giant Amgen. Immatics will receive €28.5M ($30M) upfront and up to €475M ($500M) per program and Amgen will be responsible for clinical development, manufacturing and […]

January 9, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

UPDATE: J&J and Actelion settle on a price, R&D assets will be spun out

An Antibody to reduce Hospitalizations of Children starts Phase IIb trials

German Microscopy Tech raises funds to take over Imaging in Biology

Antibody Treatment for Obesity and Type 2 Diabetes enters Phase II

Phase II Failure: CureVac’s CEO explains Missed Efficacy Endpoint

Merck expands its Oncology Pipeline beyond Checkpoint Inhibitors

UPDATE: The 5 Hottest European Biotechs in 2017 according to JP Morgan

Dutch Biotech Takes over Sustainable Coca Cola Bottles Project

Stem Cells in your Teeth can be Stimulated to Naturally Repair Cavities

Qiagen acquires Multi Omics Company to boost its Bioinformatics services

Top European VC and CRO fund Young Metabolic Disease Biotech

German Immuno-Oncology Biotech partners up with Biotech Giant Amgen

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!